Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

FGF-23 levels in patients with AKI and risk of adverse outcomes.

Publication ,  Journal Article
Leaf, DE; Wolf, M; Waikar, SS; Chase, H; Christov, M; Cremers, S; Stern, L
Published in: Clin J Am Soc Nephrol
August 2012

BACKGROUND AND OBJECTIVES: Fibroblast growth factor 23 plays an important role in regulating phosphate and vitamin D homeostasis. Elevated levels of fibroblast growth factor 23 are independently associated with mortality in patients with CKD and ESRD. Whether fibroblast growth factor 23 levels are elevated and associated with adverse outcomes in patients with AKI has not been studied. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This study had 30 participants with AKI, which was defined as an increase in serum creatinine ≥ 0.3 mg/dl or ≥ 50% from baseline, and 30 controls from the general hospital wards and intensive care units. Plasma levels of C-terminal fibroblast growth factor 23 and vitamin D metabolites were measured within 24 hours of AKI onset and 5 days later. The composite endpoint was death or need for renal replacement therapy. RESULTS: Enrollment fibroblast growth factor 23 levels were significantly higher among participants with AKI than controls (median [interquartile range]=1471 [224-2534] versus 263 [96-574] RU/ml, P=0.003). Enrollment fibroblast growth factor 23 correlated negatively with 25-hydroxyvitamin D (r=-0.43, P<0.001) and 1,25-dihydroxyvitamin D (r=-0.39, P=0.003) and positively with phosphate (r=0.32, P=0.02) and parathyroid hormone (r=0.37, P=0.005). Among participants with AKI, enrollment fibroblast growth factor 23 (but not other serum parameters) was significantly associated with the composite endpoint, even after adjusting for age and enrollment serum creatinine (11 events; adjusted odds ratio per 1 SD higher ln[fibroblast growth factor 23]=13.73, 95% confidence interval=1.75-107.50). CONCLUSIONS: Among patients with AKI, fibroblast growth factor 23 levels are elevated and associated with greater risk of death or need for renal replacement therapy.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clin J Am Soc Nephrol

DOI

EISSN

1555-905X

Publication Date

August 2012

Volume

7

Issue

8

Start / End Page

1217 / 1223

Location

United States

Related Subject Headings

  • Vitamin D
  • Urology & Nephrology
  • Up-Regulation
  • Time Factors
  • Risk Factors
  • Risk Assessment
  • Renal Replacement Therapy
  • Prospective Studies
  • Prognosis
  • Pilot Projects
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Leaf, D. E., Wolf, M., Waikar, S. S., Chase, H., Christov, M., Cremers, S., & Stern, L. (2012). FGF-23 levels in patients with AKI and risk of adverse outcomes. Clin J Am Soc Nephrol, 7(8), 1217–1223. https://doi.org/10.2215/CJN.00550112
Leaf, David E., Myles Wolf, Sushrut S. Waikar, Herbert Chase, Marta Christov, Serge Cremers, and Leonard Stern. “FGF-23 levels in patients with AKI and risk of adverse outcomes.Clin J Am Soc Nephrol 7, no. 8 (August 2012): 1217–23. https://doi.org/10.2215/CJN.00550112.
Leaf DE, Wolf M, Waikar SS, Chase H, Christov M, Cremers S, et al. FGF-23 levels in patients with AKI and risk of adverse outcomes. Clin J Am Soc Nephrol. 2012 Aug;7(8):1217–23.
Leaf, David E., et al. “FGF-23 levels in patients with AKI and risk of adverse outcomes.Clin J Am Soc Nephrol, vol. 7, no. 8, Aug. 2012, pp. 1217–23. Pubmed, doi:10.2215/CJN.00550112.
Leaf DE, Wolf M, Waikar SS, Chase H, Christov M, Cremers S, Stern L. FGF-23 levels in patients with AKI and risk of adverse outcomes. Clin J Am Soc Nephrol. 2012 Aug;7(8):1217–1223.

Published In

Clin J Am Soc Nephrol

DOI

EISSN

1555-905X

Publication Date

August 2012

Volume

7

Issue

8

Start / End Page

1217 / 1223

Location

United States

Related Subject Headings

  • Vitamin D
  • Urology & Nephrology
  • Up-Regulation
  • Time Factors
  • Risk Factors
  • Risk Assessment
  • Renal Replacement Therapy
  • Prospective Studies
  • Prognosis
  • Pilot Projects